Plant Name: Saposhnikovia divaricata
Taxonomic Information:
Plant ID: NPO16755
Plant Latin Name: Saposhnikovia divaricata
Taxonomy Genus: Saposhnikovia
Taxonomy Family: Apiaceae
Plant External Links:
NCBI TaxonomyDB:
203717
Plant-of-the-World-Online:
847902-1
Used in Medicines:
Country/Region:
ChinaTraditional Medicine System:
TCM; KampoGeographical Distribution:
China; Mongolia; South Africa
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| ADORA3; ADORA2A; ADORA1; | |
| TSHR; | |
| TRPA1; | |
| ADK; | |
| CA9; | |
| MAPT; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2A13 | Cytochrome P450 2A13 | Q16696 | CHEMBL3542436 |
| Cytochrome P450 family 2 | CYP2A6 | Cytochrome P450 2A6 | P11509 | CHEMBL5282 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Enzyme_unclassified | ADK | Adenosine kinase | P55263 | CHEMBL3589 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family A GPCR) | ADORA2A | Adenosine A2a receptor | P29274 | CHEMBL251 |
| Small molecule receptor (family A GPCR) | ADORA1 | Adenosine A1 receptor | P30542 | CHEMBL226 |
| Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤1μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 5.080E-10 | 1.106E-05 | CYP1A2, CYP2A13, CYP2A6, CYP2C19 |
| MF | GO:0060089; molecular transducer activity | GO:0001609; G-protein coupled adenosine receptor activity | 6.403E-09 | 6.971E-05 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0009987; cellular process | GO:0001973; adenosine receptor signaling pathway | 1.536E-08 | 1.115E-04 | ADORA1, ADORA2A, ADORA3 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 4.017E-08 | 1.750E-04 | CYP1A2, CYP2A6, CYP2C19 |
| MF | GO:0003824; catalytic activity | GO:0008392; arachidonic acid epoxygenase activity | 1.240E-07 | 3.374E-04 | CYP2A13, CYP2A6, CYP2C19 |
| CC | GO:0044464; cell part | GO:0030673; axolemma | 1.021E-07 | 3.374E-04 | ADORA1, ADORA2A, MAPT |
| MF | GO:0003824; catalytic activity | GO:0008389; coumarin 7-hydroxylase activity | 3.538E-07 | 5.906E-04 | CYP2A13, CYP2A6 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 8.739E-07 | 1.057E-03 | CYP1A2, CYP2A13, CYP2A6, CYP2C19 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.084E-06 | 1.124E-03 | CYP2A13, CYP2A6, CYP2C19 |
| CC | GO:0044464; cell part | GO:0099056; integral component of presynaptic membrane | 1.061E-06 | 1.124E-03 | ADORA1, ADORA2A |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 2.131E-06 | 1.785E-03 | CYP1A2, CYP2A13, CYP2A6, CYP2C19 |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.561E-06 | 2.066E-03 | CYP1A2, CYP2A13, CYP2C19 |
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 5.300E-06 | 3.979E-03 | CYP1A2, CYP2C19 |
| BP | GO:0008152; metabolic process | GO:0009804; coumarin metabolic process | 7.417E-06 | 5.210E-03 | CYP2A13, CYP2A6 |
| BP | GO:0032501; multicellular organismal process | GO:0048143; astrocyte activation | 1.271E-05 | 7.685E-03 | ADORA2A, MAPT |
| CC | GO:0044456; synapse part | GO:0099055; integral component of postsynaptic membrane | 1.271E-05 | 7.685E-03 | ADORA1, ADORA2A |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.588E-05 | 9.344E-03 | CYP1A2, CYP2C19 |
Enriched KEGG Pathways of Target Proteins (Activity≤1μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.267E-07 | 3.928E-06 | CYP2A6, CYP2A13, CYP1A2, CYP2C19 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 8.456E-06 | 7.769E-05 | CYP2A6, CYP1A2, CYP2C19 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 1.002E-05 | 7.769E-05 | CYP2A6, CYP2A13, CYP1A2 |
| 09130 Environmental Information Processing | 09133 Signaling molecules and interaction | hsa04080 | Neuroactive ligand-receptor interaction | 1.633E-05 | 1.012E-04 | ADORA2A, ADORA3, ADORA1, TSHR |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04024 | cAMP signaling pathway | 1.998E-04 | 8.848E-04 | ADORA2A, ADORA1, TSHR |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 3.297E-06 | 5.110E-05 | CYP2A6, CYP1A2 |
| 09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 4.992E-04 | 1.934E-03 | ADORA1, TSHR |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.328E-04 | 6.861E-04 | CYP1A2, CYP2C19 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 6.722E-04 | 2.315E-03 | CYP2A6, CYP1A2 |
| 09130 Environmental Information Processing | 09132 Signal transduction | hsa04071 | Sphingolipid signaling pathway | 2.265E-03 | 7.023E-03 | ADORA3, ADORA1 |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | ADORA1; |
| A00-B99: Certain infectious and parasitic diseases | Sepsis | A40, A41 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Heart failure | I50 | ADORA1; |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | ADORA1; ADORA2A; |
| C00-D49: Neoplasms | Renal cancer | C64 | CA9; |
| N00-N99: Diseases of the genitourinary system | Renal failure | N17, N18, N19 | ADORA1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ADORA1; MAPT; |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ADORA1; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Radionuclide imaging | W88 | ADORA2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ADORA1; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Hypertension | I10-I16 | ADORA1; ADORA2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hypertriglyceridemia | E78.1, E78.2, E78.3, I47-I49 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Coronary disorder diagnosis | I20-I25 | ADORA2A; |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3; |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
| I00-I99: Diseases of the circulatory system | Acute and chronic heart failure | I50 | ADORA1; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Convulsions | R56.0 | ADK; |
| J00-J99: Diseases of the respiratory system | Throat irritation | J39.2 | TRPA1; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | CA9; |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; |
| R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Fatigue | R53 | ADORA1; |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR; |
| NA: NA | Hepatitis C virus infection | NA | ADORA3; |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ADORA2A; ADK; TRPA1; |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ADORA1; ADORA2A; |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | ADORA2A; |
| I00-I99: Diseases of the circulatory system | Cardiac disease | I00-I99 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Orthostatic hypotension | I95.1 | ADORA1; |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
| J00-J99: Diseases of the respiratory system | Chronic obstructive pulmonary disease | J40-J44, J47 | ADORA2A; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | ADORA2A; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | ADORA1; |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ADORA2A; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | ADORA1; |
| G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ADK; |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | ADORA1; ADORA2A; |
| C00-D49: Neoplasms | Cancer | C00-C96 | ADORA3; CA9; |
| I00-I99: Diseases of the circulatory system | Cardiac arrhythmias | I47-I49 | ADORA1; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3; |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA1; ADORA2A; ADORA3; |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | ADK; |
>> Profiles of ingredients and activity landscape
>> Collective molecular activities profile at 10μM cutoff
>> Targets derived from weak experimental activities
